144 related articles for article (PubMed ID: 9108442)
1. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
Li D; Dragan Y; Jordan VC; Wang M; Pitot HC
Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442
[TBL] [Abstract][Full Text] [Related]
2. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days.
Schild LJ; Divi RL; Beland FA; Churchwell MI; Doerge DR; Gamboa da Costa G; Marques MM; Poirier MC
Cancer Res; 2003 Sep; 63(18):5999-6003. PubMed ID: 14522927
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling.
Divi RL; Osborne MR; Hewer A; Phillips DH; Poirier MC
Cancer Res; 1999 Oct; 59(19):4829-33. PubMed ID: 10519392
[TBL] [Abstract][Full Text] [Related]
4. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver.
Hashiba M; Kasahara T; Kim SY; Shibutani S; Degawa M
Cancer Sci; 2006 Jun; 97(6):468-77. PubMed ID: 16734724
[TBL] [Abstract][Full Text] [Related]
5. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene.
Gamboa da Costa G; Pereira PC; Churchwell MI; Beland FA; Marques MM
Chem Res Toxicol; 2007 Feb; 20(2):300-10. PubMed ID: 17261033
[TBL] [Abstract][Full Text] [Related]
6. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen.
Shibutani S; Suzuki N; Laxmi YR; Schild LJ; Divi RL; Grollman AP; Poirier MC
Cancer Res; 2003 Aug; 63(15):4402-6. PubMed ID: 12907611
[TBL] [Abstract][Full Text] [Related]
7. Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods.
Schild LJ; Phillips DH; Osborne MR; Hewer A; Beland FA; Churchwell MI; Brown K; Gaskell M; Wright E; Poirier MC
Mutagenesis; 2005 Mar; 20(2):115-24. PubMed ID: 15755801
[TBL] [Abstract][Full Text] [Related]
8. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
[TBL] [Abstract][Full Text] [Related]
9. Organ specificity of DNA adduct formation by tamoxifen and alpha-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment.
Phillips DH; Hewer A; Osborne MR; Cole KJ; Churchill C; Arlt VM
Mutagenesis; 2005 Jul; 20(4):297-303. PubMed ID: 15928012
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats.
Dragan YP; Shimel RJ; Bahnub N; Sattler G; Vaughan JR; Jordan VC; Pitot HC
Toxicol Sci; 1998 Jun; 43(2):129-38. PubMed ID: 9710954
[TBL] [Abstract][Full Text] [Related]
11. Inefficient repair of tamoxifen-DNA adducts in rats and mice.
Kim SY; Suzuki N; Laxmi YR; Shibutani S
Drug Metab Dispos; 2006 Feb; 34(2):311-7. PubMed ID: 16299164
[TBL] [Abstract][Full Text] [Related]
12. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
[TBL] [Abstract][Full Text] [Related]
13. Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology.
Mahadevan B; Arora V; Schild LJ; Keshava C; Cate ML; Iversen PL; Poirier MC; Weston A; Pereira C; Baird WM
Mol Carcinog; 2006 Feb; 45(2):118-25. PubMed ID: 16329150
[TBL] [Abstract][Full Text] [Related]
14. Formation of tamoxifen-DNA adducts in human endometrial explants exposed to alpha-hydroxytamoxifen.
Kim SY; Suzuki N; Laxmi YR; McGarrigle BP; Olson JR; Sharma M; Sharma M; Shibutani S
Chem Res Toxicol; 2005 May; 18(5):889-95. PubMed ID: 15892583
[TBL] [Abstract][Full Text] [Related]
15. Patterns of DNA adduct formation in liver and mammary epithelial cells of rats treated with 7,12-dimethylbenz(a)anthracene, and selective effects of chemopreventive agents.
Izzotti A; Camoirano A; Cartiglia C; Grubbs CJ; Lubet RA; Kelloff GJ; De Flora S
Cancer Res; 1999 Sep; 59(17):4285-90. PubMed ID: 10485473
[TBL] [Abstract][Full Text] [Related]
16. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients.
Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM
Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226
[TBL] [Abstract][Full Text] [Related]
17. Quantification of tamoxifen DNA adducts using on-line sample preparation and HPLC-electrospray ionization tandem mass spectrometry.
Gamboa da Costa G; Marques MM; Beland FA; Freeman JP; Churchwell MI; Doerge DR
Chem Res Toxicol; 2003 Mar; 16(3):357-66. PubMed ID: 12641436
[TBL] [Abstract][Full Text] [Related]
18. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of lower genotoxicity of toremifene compared with tamoxifen.
Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW
Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807
[TBL] [Abstract][Full Text] [Related]
20. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen.
Shibutani S; Ravindernath A; Suzuki N; Terashima I; Sugarman SM; Grollman AP; Pearl ML
Carcinogenesis; 2000 Aug; 21(8):1461-7. PubMed ID: 10910945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]